204 related articles for article (PubMed ID: 37545464)
1. Global analysis of iron metabolism-related genes identifies potential mechanisms of gliomagenesis and reveals novel targets.
Zhang J; Zhao L; Xuan S; Liu Z; Weng Z; Wang Y; Dai K; Gu A; Zhao P
CNS Neurosci Ther; 2024 Feb; 30(2):e14386. PubMed ID: 37545464
[TBL] [Abstract][Full Text] [Related]
2. Bortezomib inhibits growth and sensitizes glioma to temozolomide (TMZ) via down-regulating the FOXM1-Survivin axis.
Tang JH; Yang L; Chen JX; Li QR; Zhu LR; Xu QF; Huang GH; Zhang ZX; Xiang Y; Du L; Zhou Z; Lv SQ
Cancer Commun (Lond); 2019 Dec; 39(1):81. PubMed ID: 31796105
[TBL] [Abstract][Full Text] [Related]
3. Grade scoring system reveals distinct molecular subtypes and identifies KIF20A as a novel biomarker for predicting temozolomide treatment efficiency in gliomas.
Ye L; Tong S; Wang Y; Wang Y; Ma W
J Cancer Res Clin Oncol; 2023 Sep; 149(12):9857-9876. PubMed ID: 37248320
[TBL] [Abstract][Full Text] [Related]
4. Gene expression profiling predicts response to temozolomide in malignant gliomas.
Yoshino A; Ogino A; Yachi K; Ohta T; Fukushima T; Watanabe T; Katayama Y; Okamoto Y; Naruse N; Sano E; Tsumoto K
Int J Oncol; 2010 Jun; 36(6):1367-77. PubMed ID: 20428759
[TBL] [Abstract][Full Text] [Related]
5. Comprehensive Analysis Reveals a 4-Gene Signature in Predicting Response to Temozolomide in Low-Grade Glioma Patients.
Wang Q; He Z; Chen Y
Cancer Control; 2019; 26(1):1073274819855118. PubMed ID: 31167546
[TBL] [Abstract][Full Text] [Related]
6. Integration analysis of cell division cycle-associated family genes revealed potential mechanisms of gliomagenesis and constructed an artificial intelligence-driven prognostic signature.
Yu K; Tian Q; Feng S; Zhang Y; Cheng Z; Li M; Zhu H; He J; Li M; Xiong X
Cell Signal; 2024 Jul; 119():111168. PubMed ID: 38599441
[TBL] [Abstract][Full Text] [Related]
7. Inhibitory effects of temozolomide on glioma cells is sensitized by RSL3-induced ferroptosis but negatively correlated with expression of ferritin heavy chain 1 and ferritin light chain.
Yang FC; Wang C; Zhu J; Gai QJ; Mao M; He J; Qin Y; Yao XX; Wang YX; Lu HM; Cao MF; He MM; Wen XM; Leng P; Cai XW; Yao XH; Bian XW; Wang Y
Lab Invest; 2022 Jul; 102(7):741-752. PubMed ID: 35351965
[TBL] [Abstract][Full Text] [Related]
8. Brachyury Is Associated with Glioma Differentiation and Response to Temozolomide.
Pinto F; Costa ÂM; Andrade RP; Reis RM
Neurotherapeutics; 2020 Oct; 17(4):2015-2027. PubMed ID: 32785847
[TBL] [Abstract][Full Text] [Related]
9. Gene expression profiles predicting the response to IFN-β and a combination of temozolomide and IFN-β in malignant gliomas.
Yoshino A; Tashiro S; Ogino A; Yachi K; Ohta T; Fukushima T; Watanabe T; Katayama Y; Okamoto Y; Sano E; Tsumoto K
Int J Oncol; 2011 Sep; 39(3):529-42. PubMed ID: 21805051
[TBL] [Abstract][Full Text] [Related]
10. ATRX/EZH2 complex epigenetically regulates FADD/PARP1 axis, contributing to TMZ resistance in glioma.
Han B; Meng X; Wu P; Li Z; Li S; Zhang Y; Zha C; Ye Q; Jiang C; Cai J; Jiang T
Theranostics; 2020; 10(7):3351-3365. PubMed ID: 32194873
[No Abstract] [Full Text] [Related]
11. Role of COL6A2 in malignant progression and temozolomide resistance of glioma.
Hong X; Zhang J; Zou J; Ouyang J; Xiao B; Wang P; Peng X
Cell Signal; 2023 Feb; 102():110560. PubMed ID: 36521657
[TBL] [Abstract][Full Text] [Related]
12. miR-1297 sensitizes glioma cells to temozolomide (TMZ) treatment through targeting adrenomedullin (ADM).
He Z; Cheng M; Hu J; Liu L; Liu P; Chen L; Cao D; Tang J
J Transl Med; 2022 Oct; 20(1):443. PubMed ID: 36183123
[TBL] [Abstract][Full Text] [Related]
13. Identification of a three-long non-coding RNA signature for predicting survival of temozolomide-treated isocitrate dehydrogenase mutant low-grade gliomas.
Li R; Chen W; Mao P; Wang J; Jing J; Sun Q; Wang M; Yu X
Exp Biol Med (Maywood); 2021 Jan; 246(2):187-196. PubMed ID: 33028081
[TBL] [Abstract][Full Text] [Related]
14. Mutant IDH1 Enhances Temozolomide Sensitivity via Regulation of the ATM/CHK2 Pathway in Glioma.
Lin L; Cai J; Tan Z; Meng X; Li R; Li Y; Jiang C
Cancer Res Treat; 2021 Apr; 53(2):367-377. PubMed ID: 33070553
[TBL] [Abstract][Full Text] [Related]
15. Exosomal circWDR62 promotes temozolomide resistance and malignant progression through regulation of the miR-370-3p/MGMT axis in glioma.
Geng X; Zhang Y; Lin X; Zeng Z; Hu J; Hao L; Xu J; Wang X; Wang H; Li Q
Cell Death Dis; 2022 Jul; 13(7):596. PubMed ID: 35817771
[TBL] [Abstract][Full Text] [Related]
16. ZNF300 enhances temozolomide resistance in gliomas by regulating lncRNA SNHG12.
Fu J; Peng J; Tu G
Gen Physiol Biophys; 2022 Jul; 41(4):349-355. PubMed ID: 35938968
[TBL] [Abstract][Full Text] [Related]
17. Knockdown of circHIPK3 Facilitates Temozolomide Sensitivity in Glioma by Regulating Cellular Behaviors Through miR-524-5p/KIF2A-Mediated PI3K/AKT Pathway.
Yin H; Cui X
Cancer Biother Radiopharm; 2021 Sep; 36(7):556-567. PubMed ID: 32833501
[No Abstract] [Full Text] [Related]
18. Inhibition of mitochondrial carrier homolog 2 (MTCH2) suppresses tumor invasion and enhances sensitivity to temozolomide in malignant glioma.
Yuan Q; Yang W; Zhang S; Li T; Zuo M; Zhou X; Li J; Li M; Xia X; Chen M; Liu Y
Mol Med; 2021 Jan; 27(1):7. PubMed ID: 33509092
[TBL] [Abstract][Full Text] [Related]
19. CD147 confers temozolomide resistance of glioma cells via the regulation of β-TrCP/Nrf2 pathway.
Bu X; Qu X; Guo K; Meng X; Yang X; Huang Q; Dou W; Feng L; Wei X; Gao J; Sun W; Chao M; Han L; Hu Y; Shen L; Zhang J; Wang L
Int J Biol Sci; 2021; 17(12):3013-3023. PubMed ID: 34421346
[No Abstract] [Full Text] [Related]
20. CD90
Xue BZ; Xiang W; Zhang Q; Wang HF; Zhou YJ; Tian H; Abdelmaksou A; Xue J; Sun MX; Yi DY; Xiong NX; Jiang XB; Zhao HY; Fu P
Stem Cell Res Ther; 2021 Jul; 12(1):394. PubMed ID: 34256854
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]